Aptose Biosciences Inc. (APS:TSX) Investor Relations Material

Overview

Aptose Biosciences is a biotechnology company focused on developing novel oncology therapies to treat life-threatening cancers such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The company's approach is to utilize insights into the genetic and epigenetic profiles of certain cancers and patient populations to create targeted medicines for precision treatment based on a patient's specific gene expression signature. This strategy is intended to not only maximize efficacy but also minimize the cytotoxic side effects associated with traditional treatments. Aptose Biosciences is building a pipeline of first-in-class agents directed at dysregulated processes and signaling pathways to address the unmet needs of patients with hematologic malignancies.

Frequently Asked Questions

What is Aptose Biosciences Inc.'s ticker?

Aptose Biosciences Inc.'s ticker is APS

What exchange is Aptose Biosciences Inc. traded on?

The company's shares trade on the TSX stock exchange

Where are Aptose Biosciences Inc.'s headquarters?

They are based in San Diego, California

How many employees does Aptose Biosciences Inc. have?

There are 11-50 employees working at Aptose Biosciences Inc.

What is Aptose Biosciences Inc.'s website?

It is http://www.aptose.com/

What type of sector is Aptose Biosciences Inc.?

Aptose Biosciences Inc. is in the Healthcare sector

What type of industry is Aptose Biosciences Inc.?

Aptose Biosciences Inc. is in the Biotechnology industry

Who are Aptose Biosciences Inc.'s peers and competitors?

The following five companies are Aptose Biosciences Inc.'s industry peers:

- Prothena Corp

- Galera Therapeutics, Inc.

- Fulcrum Therapeutics Inc

- Immunic

- Immunovant, Inc.